An Approach to the Inheritance of the Sesquiterpene Chemotypes within <i>Petasites hybridus</i>

Chizzola, Remigius; Langer, Theodor; Franz, Chlodwig

doi:10.1055/s-2006-947226

Cited by 17 publications

(9 citation statements)

References 8 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differences in sesquiterpene profiles in different populations of the species and the existence of hemovarieties with furanoeremofilanes (furanopetasin hemotype) have been established [19][20][21]. It should be borne in mind that only the petasin chemotype is considered suitable for pharmaceutical purposes [22]. In the studied Bulgarian extract, the petasin and its isomers (isopetasin and neopetasin) are in the higher content.…”

Section: Discussionmentioning

confidence: 93%

Anti-cancer effect of Petasites hybridus L. (Butterbur) root extract on breast cancer cell lines

Tzoneva

Uzunova

Stoyanova

et al. 2021

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

In this study, we present initial data for the potential anti-cancer effects of standardized Bulgarian Petasites hybridus root extract against breast cancer cells. The results showed that Butterbur extract (BE) caused a dose-dependent selective reduction in viability with concomitant increase of apoptosis in human breast cancer cells after 72 h treatment. We found the highest cytotoxicity of BE to MDA-MB-231 cells (IC 50 -520 μg/mL), followed by the MCF-7 cancer cell line (IC 50 -865 μg/mL). At the same time, the extract exhibited very low cytotoxicity to the non-tumorigenic L929 cell line (two-fold higher inhibitory concentration -1252 μg/mL). As a result of our experiments we made the conclusion that Butterbur root extract shows selective high cytotoxicity and nucleus alterations in cancer cells comparing to non-cancerous cells.

show abstract

Section: Discussionmentioning

confidence: 93%

Anti-cancer effect of Petasites hybridus L. (Butterbur) root extract on breast cancer cell lines

Tzoneva

Uzunova

Stoyanova

et al. 2021

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

show abstract

“…We report the case of Petadolex ® , a defined Petasites hybridus (butterbur) extract used as migraine preventive treatment in adults. The extract is primarily composed of sesquiterpene esters, mainly of the petasin and the furanopetasin chemotype [2] and constitutes a mixture of petasin, isopetasin, neopetasin as well as furanoeremophilanes and eremophilanlactones. In the following this mixture is referred to as ‘petasin’.…”

Section: Introductionmentioning

confidence: 99%

Hepatobiliary Events in Migraine Therapy with Herbs—The Case of Petadolex, A Petasites Hybridus Extract

Anderson

Borlak

2019

JCM

View full text Add to dashboard Cite

Petadolex®, a defined butterbur extract has clinically proven efficacy against migraine attacks. However, spontaneous reports indicate cases of herbal induced liver injury (HILI). While most HILI patients presented mild serum biochemistry changes (<3 ULN, dose range 50 to 225 mg/day; treatment duration 4–730 days) nine developed severe HILI (average time-to-onset 103 days, ALT-range 3–153; AST 2–104-fold ULN). HILI cases resolved after medication withdrawal though two patients required liver transplantation. Liver biopsies revealed an inconsistent injury pattern, i.e. necrosis, macrovesicular steatosis, inflammation, cholestasis, and bile duct proliferation. Causality assessment rated 3 cases likely, 13 possible, 8 unlikely and 24 as unclassifiable/unclassified. Note, 22 patients reported hepatotoxic co-medications especially during periods of pain. A no-observable-adverse-effect-level at 15-fold of the maximal clinical dose (3 mg/kg/day MCD) was established for rats. At >45 and 90-fold MCD bile duct hyperplasia was observed but could not be confirmed in an explorative minipig study at 218-fold MCD. Human hepatocyte studies at 49-fold Cmax serum petasins (=active ingredient) and therapeutic Ibuprofen, Paracetamol and Naratriptan concentrations evidenced liver transaminase and CYP-monooxygenase changes. Collectively, Petadolex® HILI cases are rare, idiosyncratic and frequently confounded by co-medications. A physician-supervised self-medication plan with herbs and pain relief medication is needed to minimize risk for HILI.

show abstract

“… 21 , 33 , 37 – 43 The active components are sesquiterpene esters of the eremophilane type, and their bioactivity is attributed to petasine and isopetasine. 44 , 45 Studies by Shimoda et al 46 showed that the effective constituent in the extract of Petasites japonicus was petasine, which had inhibitory effects on leukotriene synthesis 39 and bronchoconstriction. 47 Another eremophilane-type sesquiterpene ketone, namely, Fukinones (1 and 3), 48 exerted suppressive mechanisms in a type I hypersensitivity model in rats and IgE-sensitized RBL-2H3 cells through inhibition of smooth muscle constriction and inhibition of degranulation, leukotriene release, and TNF production by mast cells.…”

Section: Discussionmentioning

confidence: 99%

Bicyclic eremophilane-type petasite sesquiterpenes potentiate peroxisome proliferator–activated receptor γ activator–mediated inhibition of dendritic cells

Arizmendi

Hou

Guo

et al. 2018

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Dendritic cell (DC) activation induces expression of co-stimulatory surface molecules, as well as migration into secondary lymphoid organs, where they activate naïve T-cells. A family of plant derivatives, eremophilane-type petasite sesquiterpenes, can regulate the immune system through DC targeting due to their anti-inflammatory effects. Peroxisome proliferator–activated receptor gamma (PPARγ) is involved in inhibition of inflammatory responses and induction of DCs to acquire a mucosal phenotype. Since mucosal DCs are central in innate immune responses, we hypothesized that eremophilane-type petasite sesquiterpenes exerted their anti-inflammatory effects by inhibiting DC maturation and activation through PPARγ. This study assessed the bicyclic eremophilane-type petasite sesquiterpene compounds Fukinone and 10βH-8α,12-Epidioxyeremophil-7(11)-en-8β-ol (ZYFDC21 and ZYFDC22) in the maturation and activation of mouse DC. We measured surface expression of co-stimulatory molecules by flow cytometry and cell-free supernatant cytokine production upon lipopolysaccharide stimulation by enzyme-linked immunosorbent assays (ELISAs) in the presence or absence of PPARγ agonists. DCs were generated from C57BL/6 mice bone marrow cells and harvested. Cells were exposed to bicyclic eremophilane-type petasite sesquiterpenes ZYFDC21 or ZYFDC22 in the presence or absence of synthetic PPARγ agonists (GW1929 and TGZ) or the natural PPARγ ligand 15d-PGJ2, followed by overnight activation with LPS. We observed differences in the upregulation of surface expression of CD86, along with TNF, IL-6, and IL-12p70 released by DCs stimulated with LPS, when using combinations of bicyclic eremophilane-type petasite sesquiterpenes ZYFDC21 or ZYFDC22, and PPARγ agonists, in particular the PPARγ ligand 15d-PGJ2. Our results indicate that bicyclic eremophilane-type petasite sesquiterpenes ZYFDC21 or ZYFDC22 inhibit maturation and activation of DC, and this activity is augmented upon PPARγ activation.

show abstract

An Approach to the Inheritance of the Sesquiterpene Chemotypes within Petasites hybridus

Cited by 17 publications

References 8 publications

Anti-cancer effect of Petasites hybridus L. (Butterbur) root extract on breast cancer cell lines

Anti-cancer effect of Petasites hybridus L. (Butterbur) root extract on breast cancer cell lines

Hepatobiliary Events in Migraine Therapy with Herbs—The Case of Petadolex, A Petasites Hybridus Extract

Bicyclic eremophilane-type petasite sesquiterpenes potentiate peroxisome proliferator–activated receptor γ activator–mediated inhibition of dendritic cells

Contact Info

Product

Resources

About